CHAPTER 2.2 64 Table 1 (continued). Heart failure phase III trial characteristics Outpatient Hospitalized HF Total HFrEF HFpEF Any EF Primary sponsor Industry 78 47.9% 19 57.6% 55 48.2% 38 58.5% 190 50.7% Academic/ healthcare institution 53 32.5% 10 30.3% 39 34.2% 20 20.8% 122 32.5% NIH/ other gov agency 26 16.0% 3 9.1% 15 13.2% 7 10.8% 51 13.6% Othera 6 3.7% 1 3.0% 5 4.4% 0 0% 12 3.2% HFpEF trials were those which recruited only patients with LVEF more than or equal 40%, hospitalized HF trials evaluated therapies in acute decompensation or hospitalized patients and the remaining are categorised as non-LVEF selective trials a Other includes managed care or non-profit organisations, individual investigators and networks.
RkJQdWJsaXNoZXIy MjY0ODMw